Clinicopathological Characteristics and Prognostic Factors of Primary Bladder Signet Ring Cell Carcinoma

Liang Liu, Qiang Wang, and Haibo Yuan

Department of Urology, Baoding No. 1 Central Hospital, Baoding 071000, Hebei, China

Correspondence should be addressed to Liang Liu; mnwkll@163.com

Received 16 February 2022; Accepted 15 July 2022; Published 5 September 2022

Introduction. The aim of this study is to examine the treatment pattern and predictors of long-term survival of patients with primary signet ring cell carcinoma (PSRCC) of the urinary bladder based on the analysis of the SEER database. Methods. The 3-year and 5-year overall survival (OS) and cancer-specific survival (CSS) were calculated using the Kaplan–Meier method. Then, we compared the CSS curves by the log-rank test. The independent risk factors were determined using univariate and multivariate Cox regression. Results. The 3-year OS and CSS rates for PSRCC of the bladder were 25.3% and 33.3%. The 5-year OS and CSS rates for the entire cohort were 16.4% and 25.2%. The CSS rates, respectively, were 0, 25.0, 66.7, 33.2, 42.4, and 31.7% at 3 years and 0, 25.0, 34.3, 24.1, 27.2, and 31.7% at 5 years for none, transurethral resection of the bladder (TURB), partial cystectomy, radical cystectomy with reconstruction, pelvic exenteration, and other surgeries (P < 0.001). Multivariate analyses showed independent risk factors only including T stage, M stage, lymph node removal, and surgical approach. Conclusions. T stage, M stage, lymph node removal, and surgical approach are independent risk factors of PSRCC of the urinary bladder. TURB and radical cystectomy with reconstruction appear to provide a better outcome.

1. Introduction

Bladder tumor is one of the most common malignancies and among the most prevalent causes of tumor-associated deaths over the world. According to reports, there are more than 300,000 patients diagnosed with bladder cancer each year and more than 165,000 patients died each year [1, 2]. Primary signet ring cell carcinoma (PSRCC) of the bladder, a rare type of a bladder tumor, is accounting for approximately 0.12%–0.6% of all bladder malignancies [3, 4]. PSRCC, classified as a subtype of bladder adenocarcinoma, has the worst prognosis [5, 6]. However, according to the World Health Organization classification in 2016 for tumors of the urinary system and male genital organs, PSRCC belongs to the subtype of invasive urothelial carcinoma [7]. Patients are usually around 60 years, and the male/female ratio is about 3:1 [8, 9]. Similar to bladder urothelial carcinoma, the most familiar symptoms are hematuria in 65% of cases, which are usually painless [10]. However, the clinical manifestation is nonspecific, which leads to the patients having already reached an advanced stage and with a poor prognosis.

A standardized treatment protocol for the treatment of PSRCC has not yet been founded, and surgery is the main mode of treatment, but there is no consensus on the surgical modalities. Despite PSRCC being highly malignant, it is often ignored by clinicians due to its less incidence. For these purposes, we analyzed data on PSRCC of urinary bladder patients by the national Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. Meanwhile, we also explored the prognostic values of the clinicopathological features and survival outcomes.

2. Materials and Methods

2.1. Data Sources and Variables. Data from the NCI SEER program, collected from 2004 to 2015, were retrospectively analyzed. SEER* Stat (Surveillance Research Program, National Cancer Institute SEER* Stat software, version 8.3.8) was used to extract case-level data.
Inclusion criteria were as follows: (1) age ≥ 20 years; (2) the primary site was restricted to the urinary bladder (C67.0–C67.9) according to the ICD-O-3; (3) histology only included SRCC (ICD-O-3 8490/3); (4) confirmed by positive histology and the first positive indicator of malignancy; (5) staging was according to the 6th edition of the American Joint Committee on Cancer (AJCC) Staging Manual. Exclusion criteria were as follows: (1) without histological diagnosis; (2) without survival data; (3) histological grade or AJCC stage information was unknown; (4) the scope of regional lymph node surgery was unknown.

Patient demographics analysis included gender, age, race, and year of diagnosis. Tumor characteristics studies included tumor size, AJCC 6th stage group, T stage, N stage, M stage, and histologic grade. Treatment characteristics included surgery and lymph nodes removal.

2.2. Statistical Analysis. All data were analyzed by SPSS software version 25.0. The 3-year and 5-year overall survival (OS) and cancer-specific survival (CSS) were calculated using the Kaplan–Meier method. The overall survival curves and cancer-specific survival curves were plotted according to the Kaplan–Meier method and compared with the cancer-specific survival curves by the log-rank test. The independent risk factors of SRCC were determined using univariate and multivariate Cox regression. \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. Demographics and Tumor Characteristics. Table 1 lists the demographic and pathological characteristics of the PSRCC patients.

| Variables | N   | N%  |
|-----------|-----|-----|
| Gender    |     |     |
| Female    | 43  | 27.4|
| Male      | 114 | 72.6|
| Age, y    |     |     |
| <60       | 60  | 38.2|
| ≥60       | 97  | 61.8|
| Race      |     |     |
| White     | 133 | 84.7|
| Black     | 16  | 10.2|
| Other     | 8   | 5.1 |
| AJCC 6th stage | | |
| I         | 17  | 10.8|
| II        | 34  | 21.7|
| III       | 33  | 21.0|
| IV        | 73  | 46.5|
| AJCC 6th T stage | | |
| T1        | 19  | 12.1|
| T2        | 42  | 26.8|
| T3        | 38  | 24.2|
| T4        | 58  | 36.9|
| AJCC 6th N stage | | |
| N0        | 98  | 62.4|
| None N0   | 59  | 37.6|
| AJCC 6th M stage | | |
| M0        | 130 | 82.8|
| M1        | 27  | 17.2|
| Histologic grade | | |
| <IV       | 108 | 68.8|
| IV        | 49  | 31.2|
| Tumor size, mm | | |
| <100      | 74  | 47.1|
| 100−200   | 8   | 5.1 |
| Unknown   | 75  | 47.8|
| Year of diagnosis | | |
| 2004−2009 | 76  | 48.4|
| 2010−2015 | 81  | 51.6|
| Surgery   |     |     |
| None      | 11  | 7.0 |
| TURB      | 49  | 31.2|
| Partial cystectomy |  | |
| Radial cystectomy + reconstruction |  | |
| Pelvic exenteration |  | |
| Other     | 9   | 5.7 |
| Lymph nodes removed | | |
| None      | 82  | 52.2|
| 1 to 3 regional | 3  | 1.9 |
| 4 or more regional | 72 | 45.9 |

Table 1: Baseline demographic and clinicopathologic characteristics for PSRCC patients.

2.2 Survival Outcomes. The 3-year OS and CSS rates for PSRCC of the bladder were 25.3% and 33.3%. The 5-year OS and CSS rates for the entire cohort were 16.4% and 25.2% (Figures 1(a), 1(b)). Figure 2 shows the survival estimates stratified by AJCC stage, N stage, M stage, tumor size, surgery status, and lymph nodes removed. The CSS rates, respectively, were 0, 25.0, 66.7, 33.2, 31.7% at 3 years and 0, 25.0, 34.3, 24.1, 27.2, and 31.7% at 5 years for none, transurethral resection of the bladder (TURB), partial cystectomy, radical cystectomy with reconstruction, pelvic exenteration, and other surgeries (Figure 2(e)). The 3-year and 5-year CSS rates for patients who had not lymph nodes removed were 27.5 and 21.8%, removed 1 to 3 regional lymph nodes all were 0%, and removed 4 or more regional lymph nodes were 41.2 and 30.6%, respectively (Figure 2(f)).

3.3. Prognostic Factor Analysis. In this study, univariate analyses confirmed that risk factors of PSRCC of the bladder include tumor size, M stage, lymph node removed, and surgical approach. However, multivariate analyses showed that independent risk factors only include T stage (T3 vs. T1, HR = 4.306, 95%CI = 1.770–10.478, \( P < 0.001 \), T4 vs. T1, HR = 2.765, 95%CI = 1.218–6.277, \( P = 0.015 \)), M stage (HR = 2.343, 95%CI = 1.334–4.118, \( P = 0.003 \)), lymph node removed (4 or more regional vs. none, HR = 0.477, 95%CI = 0.247–0.922, \( P = 0.028 \)), and surgical approach (TURB vs. none, HR = 0.255, 95%CI = 0.109–0.601, \( P = 0.002 \); partial cystectomy vs. none, HR = 0.125, 95%CI = 0.040–0.389, \( P < 0.001 \); radical cystectomy with reconstruction vs. none, HR = 0.193, 95%CI = 0.080–0.467, \( P < 0.001 \); pelvic exenteration vs. none, HR = 0.132, 95%CI = 0.049–0.354, \( P < 0.001 \); and other vs. none, HR = 0.129, 95%CI = 0.039–0.424, \( P = 0.001 \) (Table 2).
4. Discussion

In this study, we aimed to discuss the prognostic value of the clinicopathological characteristics and survival outcomes in PSRCC of the urinary bladder.

PSRCC of the urinary bladder is a rare bladder malignancy, which belongs to the subtype of invasive urothelial carcinoma, with a lower incidence rate [7]. Holmång et al. [11] reported that PSRCC of the bladder patient’s occupancy 0.6% in 713 bladder cancer patients. PSRCC of the bladder was less commonly reported since the first patient was reported by Saphir [12]. Most studies were case reports, single-center studies, or small sample studies, but few researchers have analyzed the prognostic factors involved [13–17].

In this study, 106 (67.5%) patients were AJCC stage III or IV, and 49 (31.2%) patients were grade IV at diagnosis in our study, which indicates that PSRCC has the characteristics of a highly invasive and poorer prognosis. Our study agrees with the study by Akamatsu et al. [9]. In their study, the higher the histological grade, the worse the clinical prognosis (2-year OS, 43%). Besides, 46% patients were AJCC IV stage, and the survival time was not more than 2 years. The present study revealed that 62.4% patients had no lymph node metastasis and 82.8% patients had no distant metastasis. Although the PSRCC of the bladder had a lower rate of lymph node metastases and distant metastases, their prognoses were worse. According to the literature reported, the survival rate of PSRCC was lower than that of bladder urothelial carcinoma, and the natural course of the disease was 3.5 months [18]. The 5-year OS rates in our study for AJCC stages II, III, and IV were lower than those in the previous study (34.7% vs. 75%, 16.4% vs. 38%, and 6.0% vs. 12%) [10]. A Japanese study reported by Dadhania et al. [19] also demonstrated that almost half of the PSRCC patients were already at AJCC stage IV at the time of diagnosis, and the median survival was about 8 months. Besides, the surviving period of time did not exceed 2 years. However, the 5-year survival rates were nearly 50% for stages I–III in SRCC of the bladder. In our cohort, 73 (46.5%) patients were AJCC stage IV, the median survival time was 13 months, and the maximum survival time was 162 months. In addition, one study based on the SEER data in the US showed that 3-year CSS was 32% for PSRCC of the bladder, which was in accordance with our study (3-year CSS 33.3%) [18]. However, 3-year CSS was 67% of bladder urothelial carcinoma. It indicates worse outcomes for patients with bladder urothelial carcinoma than PSRCC.

Simultaneously, compared with OS curves and CSS curves, Kaplan–Meier survival curves are close (Figures 1(a), 1(b)). The common feature suggests the majority of the deaths were from SRCC causes. They further showed its poor prognosis characteristics. In our study, the 3-year OS and CSS rates for primary SRCC of the bladder were 25.3% and 33.3%. The 5-year OS and CSS rates for the entire cohort were 16.4% and 25.2%. The results were consistent with those of Wang et al. [20] (3-year CSS 40.6%), and they found that 60%–70% patients die within three years due to PSRCC of the bladder.

As for the PSRCC of the bladder, there have been differences among clinical study results of the prognostic factors for survival.

Multiple studies, compared with PSRCC of the bladder and bladder urothelial carcinoma, have shown that cystectomy, histological type, histological grade, marital status, year of diagnosis, and gender have been identified as prognostic factors, and PSRCC is a significant independent risk factor for bladder cancer [18, 20]. Wang et al. [8] suggested that age, marital status, AJCC stage, and cystectomy are
significant independent risk factors for PSRCC patients. One retrospective analysis for 45 patients from 1981–2008 years also demonstrated that tumor stage and high levels of carcinoembryonic antigen were independent risk factors for tumors [9]. In this study, univariate analyses confirmed that risk factors of PSRCC of the bladder include tumor size (unknown vs. < 100 mm, HR = 1.834, 95%CI = 1.237–2.718, \( P = 0.003 \)), M stage (HR = 2.915, 95%CI = 1.832–4.637, \( P < 0.001 \)), lymph node removed (4 or more regional vs. none, HR = 0.566, 95%CI = 0.384–0.835, \( P = 0.004 \)), and surgical approach (TURB vs. none, HR = 0.226, 95%CI = 0.107–0.477, \( P < 0.001 \)); partial cystectomy vs. none, HR = 0.111, 95% CI = 0.042–0.295, \( P < 0.001 \); partial cystectomy vs. none vs. T1, HR = 2.765, 95%CI = 1.218–6.277, \( P = 0.015 \)), M stage (HR = 2.343, 95% CI = 1.334–4.118, \( P = 0.003 \)), lymph node removed (4 or more regional vs. none, HR = 0.477, 95% CI = 0.247–0.922, \( P = 0.028 \)), and surgical approach (TURB vs. none, HR = 0.255, 95%CI = 0.109–0.601, \( P = 0.002 \); partial cystectomy vs. none, HR = 0.125, 95%CI = 0.040–0.389, \( P < 0.001 \)); pelvic exenteration vs. none, HR = 0.132, 95%CI = 0.049–0.354, \( P < 0.001 \); and other vs. none, HR = 0.129, 95%CI = 0.039–0.424, \( P = 0.001 \) (Table 2). A previous study has also demonstrated that a significant OS (HR = 0.233, 95%CI = 0.107–0.504, \( P < 0.001 \)) benefits from cystectomy and pelvic lymph node dissection for PSRCC compared with patients undergoing cystectomy only [21]. Data from our study and previous studies proved that the AJCC stage and surgical treatment were independent risk factors for PSRCC. However, our study did not show that age, year of diagnosis, and histological grade are prognostic factors.
However, there are no detailed uniform criteria due to the rarity of the tumor and the lack of clinical trials. Surgery operation and lymph nodes removal are considered protective prognostic factors in prolonged patients’ survival. Alradhi et al. [22] reported that surgery served as a significant independent protective factor for PSRCC survival. However, whether surgery should be the most appropriate surgical modality was not further analyzed. In our study, the most common surgery for PSRCC was TURB (49, 31.2%), followed by radical cystectomy with reconstruction (42, 26.8%). Due to the infiltrative pattern of growth and the early propensity of metastasis, nevertheless, certain scholars [23,24] reported that TURB and partial cystectomy carry the risk of tumor recurrence. Therefore, radical cystectomy appears to be the treatment of first choice [25–27]. According to the CSS curve, we know the survival time is the

### Table 2: Univariate and multivariable analyses of prognostic factors for PSRCC patients.

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR                  | 95%CI         | P value | HR       | 95%CI         | P value |
| Gender                     |                      |              |         |          |              |         |
| Female                     | Reference            |              |         |          |              |         |
| Male                       | 0.745                | 0.498~1.116  | 0.153   |          |              |         |
| Age, y                     |                      |              |         |          |              |         |
| <60                        | Reference            |              |         |          |              |         |
| ≥60                        | 0.857                | 0.586~1.253  | 0.425   |          |              |         |
| Race                       |                      |              |         |          |              |         |
| White                      | Reference            |              |         |          |              |         |
| Black                      | 1.550                | 0.864~2.782  | 0.142   |          |              |         |
| Other                      | 0.795                | 0.323~1.961  | 0.619   |          |              |         |
| AJCC 6th stage             |                      |              |         |          |              |         |
| I                          | Reference            |              |         |          |              |         |
| II                         | 1.395                | 0.590~3.301  | 0.448   |          |              |         |
| III                        | 1.900                | 0.814~4.437  | 0.138   |          |              |         |
| IV                         | 2.836                | 1.286~6.254  | 0.010   |          |              |         |
| AJCC 6th T stage           |                      |              |         |          |              |         |
| T1                         | Reference            |              |         |          |              |         |
| T2                         | 1.349                | 0.636~2.861  | 0.435   | 1.623    | 0.744~3.541  | 0.224   |
| T3                         | 1.785                | 0.845~3.772  | 0.129   | 4.306    | 1.770~10.478 | 0.001   |
| T4                         | 1.796                | 0.869~3.711  | 0.114   | 2.765    | 1.218~6.277  | 0.015   |
| AJCC 6th N stage           |                      |              |         |          |              |         |
| N0                         | Reference            |              |         |          |              |         |
| None                       | 1.339                | 0.910~1.971  | 0.139   | 1.275    | 0.772~2.108  | 0.343   |
| AJCC 6th M stage           |                      |              |         |          |              |         |
| M0                         | Reference            |              |         |          |              |         |
| M1                         | 2.915                | 1.832~4.637  | < 0.001 | 2.343    | 1.334~4.118  | 0.003   |
| Histologic grade           |                      |              |         |          |              |         |
| ≤III                       | Reference            |              |         |          |              |         |
| IV                         | 0.750                | 0.490~1.148  | 0.185   | 0.996    | 0.618~1.603  | 0.986   |
| Tumor size, mm             |                      |              |         |          |              |         |
| <100                       | Reference            |              |         |          |              |         |
| 100~200                    | 1.962                | 0.834~4.619  | 0.123   | 1.324    | 0.516~3.398  | 0.559   |
| Unknown                    | 1.834                | 1.237~2.718  | 0.003   | 1.268    | 0.802~2.004  | 0.310   |
| Year of diagnosis          |                      |              |         |          |              |         |
| 2004~2009                  | Reference            |              |         |          |              |         |
| 2010~2015                  | 0.875                | 0.599~1.276  | 0.487   |          |              |         |
| Surgery                    |                      |              |         |          |              |         |
| None                       | Reference            |              |         |          |              |         |
| TURB                       | 0.226                | 0.107~0.477  | < 0.001 | 0.255    | 0.109~0.601  | 0.002   |
| Partial cystectomy         | 0.111                | 0.042~0.295  | < 0.001 | 0.125    | 0.040~0.389  | < 0.001 |
| Radical cystectomy         | 0.155                | 0.072~0.335  | < 0.001 | 0.193    | 0.080~0.467  | < 0.001 |
| Pelvic exenteration        | 0.129                | 0.058~0.289  | < 0.001 | 0.132    | 0.049~0.354  | < 0.001 |
| Other                      | 0.138                | 0.046~0.419  | < 0.001 | 0.129    | 0.039~0.424  | 0.001   |
| Lymph nodes removed        |                      |              |         |          |              |         |
| None                       | Reference            |              |         |          |              |         |
| 1 to 3 regional            | 1.494                | 0.467~4.778  | 0.499   | 0.683    | 0.179~2.615  | 0.578   |
| 4 or more regional         | 0.566                | 0.384~0.835  | 0.004   | 0.477    | 0.247~0.922  | 0.028   |
shortest for unoperated patients, partial cystectomy is the highest, and other surgical treatments are close \((P = 0.001)\). In conclusion, it has been found that surgery operation has significantly improved the survival time, so surgery is the main method for PSRCC of the bladder. Recently, 70% patients were reportedly treated with surgery [28]. The number of patients with surgery \((146, 93.0\%)\) in the present study was higher than the above values, suggesting that clinicians already have more knowledge of this disease and have attracted increasing attention for surgery.

Given that up to 115 \((73.2\%)\) patients were not employing radical cystectomy with reconstruction, their treatments were oppositely prudent and might cause a worse prognosis. We gave some explanation for the condition. Firstly, patients of \(\geq 60\) years were observed in 61.8% in our study, and some of them could not undergo radical cystectomy with reconstruction due to their poor health condition. Additionally, for patients with metastasis, losing the optimal opportunities for therapy, they may be considered for palliative treatment rather than radical cystectomy with reconstruction. Finally, muscle-invasive bladder cancer is usually treated with cystectomy, radiotherapy, or systemic chemotherapy. Systemic chemotherapy could cure advanced cancer. In parallel, some recent studies demonstrated that adjuvant chemotherapy may be beneficial for PSRCC [29, 30]. Intravesical chemotherapy has been deemed as the standard treatment option for muscle-invasive bladder cancer patients after receiving TURBT, which could prevent tumor relapse, inhibit tumor growth, and prolong patient survival [31, 32]. We suggested that once PSRCC was considered by biopsy, the combination of advanced therapy should be taken into account.

Although the clinicopathological features and survival outcomes of PSRCC of the bladder were updated based on recent data, the results of our study need to be interpreted with prudence in consideration of several limitations. First, this was a retrospective review in nature. In addition, detailed therapeutic information is lacking, such as radiotherapy and chemotherapy. Future research should aim to obtain information related to radiotherapy and chemotherapy.

5. Conclusions

PSRCC of the bladder is a malignant urinary bladder tumor, with a high degree of malignancy and a poor prognosis. Therefore, PSRCC is discovered at a late stage. However, it is characterized by a low risk of lymph node metastases and distant metastases. TURB and radical cystectomy with reconstruction appear to provide a better outcome.

Data Availability

All data that support the findings of this study are openly available in the SEER database from SEER stat v.8.3.8 software.

Ethical Approval

Ethical approval is not required for the study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

LL and QW contributed to the conception and design. LL contributed to the collection and assembly of data. LL and HY contributed to the data analysis and interpretation. LL wrote the manuscript. LL, HY, and QW gave final approval of the manuscript and agreed to be accountable for all aspects of the work. All authors read and approved the final manuscript.

References

[1] S. Antoni, J. Ferlay, I. Soerjomataram, A. Znaor, A. Jemal, and F. Bray, "Bladder cancer incidence and mortality: a global overview and recent trends," European Urology, vol. 71, no. 1, pp. 96–108, 2017.
[2] C. L. Lo, Y. H. Yang, and H. T. Tseng, "A Fact-finding procedure integrating machine learning and AHP technique to predict delayed diagnosis of bladder patients with hematuria," Journal of Healthcare Engineering, pp. 1 : 3831453–10, 2021.
[3] G. Jakse, H. M. Schneider, and G. H. Jacobi, "Urachal signet-ring cell carcinoma, a rare variant of vesical adenocarcinoma: incidence and pathological criteria," The Journal of Urology, vol. 120, no. 6, pp. 764–766, 1978.
[4] M. L. Blute, J. W. Segura, R. C. Benson, and H. Zincke, "Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. The," Journal of Urology, vol. 141, no. 6, pp. 1298–1301, 1989.
[5] D. J. Grignon, J. Y. Ro, A. G. Ayala, and D. E. Johnson, "Primary signet-ring cell carcinoma of the urinary bladder," American Journal of Clinical Pathology, vol. 95, no. 1, pp. 13–20, 1991.
[6] M. S. Zaghoul, N. Nouh, M. Nazmy et al., "Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients," Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 1, pp. 13–20, 2006.
[7] P. A. Humphrey, H. Moch, A. L. Cubilla, T. M. Ulbright, and V. E. Reuter, "The 2016 WHO classification of tumours of the urinary system and male genital organs—Part B: prostate and bladder tumours," European Urology, vol. 70, no. 1, pp. 106–119, 2016.
[8] J. Wang and F. W. Wang, "Clinical characteristics and outcomes of patients with primary signet-ring cell carcinoma of the urinary bladder," Urologia Internationalis, vol. 86, no. 4, pp. 453–460, 2011.
[9] S. Akamatsu, A. Takahashi, M. Ito, and K. Ogura, "Primary signet-ring cell carcinoma of the urinary bladder," Urology, vol. 75, no. 3, pp. 615–618, 2010.
[10] L. Fiter, F. Gimeno, L. Martin, and L. Gomez Tejeda, "Signet-ring cell adenocarcinoma of bladder," Urology, vol. 41, no. 1, pp. 30–33, 1993.
[11] S. Holmång, G. Borghede, and S. L. Johansson, "Primary signet ring cell carcinoma of the bladder: a report on 10 cases," Scandinavian Journal of Urology and Nephrology, vol. 31, no. 2, pp. 145–148, 1997.
[12] O. Saphir, "Signet-ring cell carcinoma of the urinary bladder," American Journal Of Pathology, vol. 31, no. 2, pp. 223–231, 1955.
L. Bouhajja, F. Farah, N. Garbouj, and S. Ramme, “Primary signet-ring cell carcinoma of the urinary bladder: a report of two cases,” Tunisie Medicale, vol. 97, no. 1, pp. 167–169, 2019.

U. Jayarajah, D. M. H. Fernando, K. B. Herath, M. V. C. de Silva, and S. A. S Goonewardena, “Primary signet-ring cell adenocarcinoma of the urinary bladder treated with partial cystectomy: a case report and review of the literature,” Case Reports in Urology, vol. 2017, pp. 1–4, 2017.

G. E. Austin and J. Safford, “Signet ring cell carcinoma of bladder,” Urology, vol. 12, no. 4, pp. 458–460, 1978.

E. Kunze, B. Francksen, and H. Schulz, “Expression of MUC5AC apomucin in transitional cell carcinomas of the urinary bladder and its possible role in the development of mucus-secreting adenocarcinomas,” Virchows Archiv, vol. 439, no. 5, pp. 609–615, 2001.

E. Kunze, “Histogenesis of nonurothelial carcinomas in the human and rat urinary bladder,” Experimental & Toxicologic Pathology, vol. 50, no. 4-6, pp. 341–355, 1998.

M. E. Lendorf, L. H. Dohn, B. A. Dunga, A. C. Loya, and H Pappot, “An updated review on primary signet-ring cell carcinoma of the urinary bladder and report of a case,” Scandinavian Journal of Urology, vol. 52, no. 2, pp. 87–93, 2018.

V. Dadhania, B. Czerniak, and C. C. Guo, “Adenocarcinoma of the urinary bladder,” American Journal of Clinical and Experimental Urology, vol. 3, no. 2, pp. 51–63, 2015.

J. Wang, F. W. Wang, and A. Kessinger, “The impact of signet-ring cell carcinoma histology on bladder cancer outcome,” World Journal of Urology, vol. 30, no. 6, pp. 777–783, 2012.

L. Guo, L. Zhang, J. Wang, X. Zhang, and Z. Zhu, “Pelvic lymph node dissection during cystectomy with patients with bladder carcinoma with variant histology: does histologic type matter?” Frontiers in oncology, vol. 10, p. 10 : 545921, 2020.

M. Alradhi, M. Safi, S. Tao et al., “Surgery improves survival in bladder signet-ring cell carcinoma-a population-based study,” Therapeutic Advances in Urology, vol. 14, pp. 175628722210794–17562872221079473, 2022.

M. Ponz, J. Luzuriaga, J. E. Robles et al., “Primary signet-ring cell carcinoma of the urinary bladder(linitis plastica),” European Urology, vol. 11, no. 3, pp. 212–214, 1985.

H. Choi, S. Lamb, K. Pintar, and S. C. Jacobs, “Primary signet-ring cell carcinoma of the urinary bladder,” Cancer, vol. 53, no. 9, pp. 1985–1990, 1984.

A. A. Thomas, A. J. Stephenson, S. C. Campbell, J. S. Jones, and D. E Hansel, “Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder,” Human Pathology, vol. 40, no. 1, pp. 108–116, 2009.

I. Romics, E. Székely, and A. Szendroi, “Signet-ring cell carcinoma arising from the urinary bladder,” The Canadian Journal of Urology, vol. 15, no. 5, pp. 4266–4268, 2008.

A. L. Burnett, J. I. Epstein, and F. F. Marshall, “Adenocarcinoma of urinary bladder: classification and management,” Urology, vol. 37, no. 4, pp. 315–321, 1991.

N. Pugashetti, S. A. Yap, P. N. Lara, R. Gandour-Edwards, and M. A Dall’Era, “Metastatic signet-ring cell carcinoma of the urinary bladder: a novel management approach to a rare tumour,” Canadian Urological Association Journal, vol. 9, no. 3–4, pp. E204–E207, 2015.

T. Hamakawa, Y. Kojima, T. Naiki et al., “Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined S-1 and cisplatin adjuvant chemotherapy,” Case Reports in Urology, vol. 2013, Article ID 915874, 4 pages, 2013.

M. Ohtaka, T. Kawahara, Y. Kumano et al., “Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report,” Journal of Medical Case Reports, vol. 10, no. 1, p. 48, 2016.

J. Zhang, M. Li, Z. Chen, J. OuYang, and Z. Ling, “Efficacy of bladder intravesical chemotherapy with three drugs for preventing non-muscle-invasive bladder cancer recurrence,” Journal of Healthcare Engineering, pp. 1 : 2360717–7, 2021.

X. Yang, H. Lv, W. Jiang, J. Zhang, and H. Hua, “Clinical value analysis of Xiaozheng decoction combined with bladder perfusion for postoperative treatment of bladder cancer and its effect on serum miR-143 and miR-92a,” Journal of Healthcare Engineering, pp. 1 : 8177674–7, 2022.